• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Valoctocogene roxaparvovec gene therapy efficacious for hemophilia A treatment

byNhat Hung (Benjamin) LamandHarsh Shah
March 21, 2022
in Chronic Disease, Hematology, Preclinical
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. The adeno-associated virus 5 (AAV5)-based gene therapy, valoctocogene roxaparvovec (AAV5-hFVIII-SQ), resulted in sustained factor VIII production, reduced bleeding rates, and need for factor VIII concentrate supplementation.

2. All participants experienced at least one adverse event, including headaches, nausea, and increased liver enzymes.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Hemophilia A is an X-linked deficiency of coagulation factor VIII. Severe hemophilia A, characterized by factor VIII activity <1 international unit (IU)/dL, causes soft tissue bleeding and hemophilic arthropathy. Existing prophylactic therapies have improved these outcomes, but breakthrough hemorrhages still occur. Valoctocogene roxaparvovec (Valrox) is a gene therapy transducing a modified human factor VIII encoding sequence, which has been shown in phase 1-2 trials to provide sustained endogenous factor VIII production. The current phase 3 trial is to evaluate the efficacy and safety of valrox in men with severe hemophilia A. The gene therapy was given as a one-time infusion and endpoints were assessed at 49 to 52 weeks after treatment. It was found that participants achieved an elevated endogenous factor VIII activity level, along with significantly reduced bleeding events and the need for factor VIII concentrate. The most common adverse events were headaches, nausea, and increased liver enzymes such as alanine aminotransferase. This study showed that valrox was efficacious in providing endogenous factor VIII production and reducing disease burden for severe hemophilia A patients with a favorable safety profile.

Click here to read the study in NEJM

Relevant Reading: Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A

In-Depth [randomized controlled trial]: The current study was an open-label, single-group, multi-center phase 3 trial evaluating the efficacy and safety of valrox in men with severe hemophilia A. Male patients with severe hemophilia A at least 18 years of age or older, who did not have anti-AAV5 antibodies or a history of factor VIII inhibitors production and who had been on prophylactic factor VIII concentration, were included in the study. Other exclusion criteria included HIV infection and substantial liver disease. Overall, 132 participants were enrolled (including 112 participants from a previous trial), received a valrox infusion of 6×1013 vector genomes/kg body weight, and completed more than 51 weeks of follow-up and assessment. The primary outcome was the change from baseline in factor VIII activity at 49 to 52 weeks after treatment.  Secondary outcomes included changes from baseline in annualized factor VIII concentrate use and treated bleeding events. The mean change from baseline, which was below the detection limit and imputed as 1 IU/dL, in factor VIII activity level, at weeks 49 through to 52 following the infusion, was 41.9 IU/dL (95% confidence interval [CI], 34.1 to 49.7; P<0.001). The median change of factor VIII activity was 22.9 IU/dL (interquartile range, 10.9 to 61.3). In the rollover of 112 participants, after week 4, the mean and median annualized factor VIII concentrate use was 56.9 IU/kg/year (98% reduction from baseline; P<0.001) and 0 IU/kg/year. The mean and median annualized factor VIII infusion frequency, at 4 weeks after infusion, was 2.0 (98.6% reduction) and 0 infusions per year. The mean change from baseline in bleeding rates was -4.1 bleeds per year (95% CI, -5.3 to -2.8), which equated to an 83.8% reduction and was considered superior to factor VIII prophylactic therapy (P<0.001). All study participants experienced at least one adverse event – including increased alanine aminotransferase (85.8% of participants), headache (38.1%), nausea (37.3%), and increased aspartate aminotransferase (35.1%); 5 (3.7%) experienced serious adverse events attributable to the study drug. No participants died, reported thromboembolism, or withdrew due to adverse events, and none developed factor VIII inhibitors. The highly prevalent alanine aminotransferase elevation was largely resolved by glucocorticoids. The results showed that within the follow-up period, valrox resulted in a significant increase in endogenous factor VIII production and activity, as well as substantially reduced bleeding episodes and the need for exogenous factor VIII supplementation. The study noted favorable risk-benefit profiles and the plan for long-term evaluation of therapy durability.

RELATED REPORTS

Beremagene geperpavec improves wound healing in dystrophic epidermolysis bullosa

Low-dose AAVS3 gene therapy is efficacious for treating patients with hemophilia B

Betibeglogene autotemcel gene therapy effective for β-thalassemia

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: adenovirus vectorfactor VIIIgene therapyhemophiliahemophilia A
Previous Post

Kratom use disorder and withdrawal may be common in the United States

Next Post

Rucaparib compared to standard-of-care chemotherapy showed promising clinical and safe response to treat BRCA1 or BRCA2 mutated, relapsed ovarian carcinoma

RelatedReports

Video-based behavioral intervention benefits clinical skin examinations
Chronic Disease

Beremagene geperpavec improves wound healing in dystrophic epidermolysis bullosa

December 27, 2022
Separate panels of microRNAs may aid in early detection of pancreatic cancer
Chronic Disease

Low-dose AAVS3 gene therapy is efficacious for treating patients with hemophilia B

July 25, 2022
Blood type correlates with egg reserve in infertile women
Chronic Disease

Betibeglogene autotemcel gene therapy effective for β-thalassemia

February 7, 2022
Non-invasive prenatal testing linked to decreased diagnostic testing
Gastroenterology

Lentiviral gene therapy treatment for adenosine deaminase deficiency

June 25, 2021
Next Post
Quick Take: Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma

Rucaparib compared to standard-of-care chemotherapy showed promising clinical and safe response to treat BRCA1 or BRCA2 mutated, relapsed ovarian carcinoma

Multidrug induction therapy increases remission from lupus nephritis

Iberdomide elicits SRI-4 response in patients with systemic lupus erythematosus

Preoperative bilateral breast imaging may reduce contralateral cancer recurrence

Ribociclib in addition to letrozole increases overall survival compared to letrozole alone

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Rocatinlimab may be effective in the treatment of moderate-to-severe atopic dermatitis
  • Gender-affirming hormones improve psychosocial functioning in transgender youth
  • Left atrial reservoir strain improves ischemic stroke risk prediction in low-risk patients
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options